GlassScriptPhysician profile
Reem Gonnah
NPI 1376047084
$4,420.03
in general payments reported to CMS, 2019-2025
17 companies · $371 in 2025
The $371 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $161 · 2021: $972 · 2022: $783 · 2023: $1,188 · 2024: $676 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,163 · Travel and Lodging: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,162.92 |
| Travel and Lodging | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,543.23 | 2019-2024 | Constellation, Clareon, Rhopressa |
| Abbvie INC. | $489.97 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $271.81 | 2023-2024 | Acthar |
| Biotissue Holdings INC. | $253.38 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $230.65 | 2019-2024 | Eylea, Eylea Hd |
| Alimera Sciences, INC. | $210.75 | 2022-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $210.33 | 2023 | |
| Bausch & Lomb Americas INC. | $140.11 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $134.13 | 2020-2021 | |
| Coherus Oncology, INC. | $133.02 | 2023 | |
| Eyepoint US, INC. | $125.00 | 2023 | |
| Ani Pharmaceuticals, INC. | $125.00 | 2025 | Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $121.46 | 2023 | Syfovre |
| Regeneron Pharmaceuticals, INC. | $120.82 | 2025 | Eylea Hd |
| Allergan, INC. | $119.28 | 2019-2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $99.33 | 2022 | |
| Biogen, INC. | $91.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reem Gonnah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.